Sentynl, under Zydus Lifesciences, acquired global rights for Zokinvy, the first FDA-approved Progeria treatment. An acquisition milestone in expanding the rare disease medicines portfolio, focusing on supporting patients.
- News Source Indiatimes (Click to view full news): CLICK HERE
0 Comments:
Leave a Reply